StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.06−0.03 (-2.75%)

Close on Nov 18, 2026Market cap $282.13MP/E –Yield –

Autolus Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Autolus Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $117.39M, up 292.2% year over year. For fiscal 2025 it was $75.39M, up 644.9% from the year before. The highest annual figure on record is $75.39M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$75.39M+644.9%
FY2024Dec 31, 2024$10.12M+496.0%
FY2023Dec 31, 2023$1.70M+20.7%
FY2018Sep 30, 2018$1.41M-16.9%
FY2017Sep 30, 2017$1.69M+39.7%
FY2016Sep 30, 2016$1.21M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$45.69M+118.4%
Q1 FY2026CQ1 2026Mar 31, 2026$26.22M+191.9%
Q4 FY2025CQ4 2025Dec 31, 2025$24.29M+83655.2%
Q3 FY2025CQ3 2025Sep 30, 2025$21.19M–
Q2 FY2025CQ2 2025Jun 30, 2025$20.92M–
Q1 FY2025CQ1 2025Mar 31, 2025$8.98M-11.0%
Q4 FY2024CQ4 2024Dec 31, 2024$29.00K-89.2%
Q3 FY2024CQ3 2024Sep 30, 2024$0-100.0%
Q2 FY2024CQ2 2024Jun 30, 2024$0-100.0%
Q1 FY2024CQ1 2024Mar 31, 2024$10.09M+3187.0%
Q1 FY2021CQ1 2021Mar 31, 2021$269.00K-39.3%
Q2 FY2020CQ2 2020Jun 30, 2020$293.00K+26.8%
Q1 FY2020CQ1 2020Mar 31, 2020$338.00K–
Q4 FY2018CQ3 2018Sep 30, 2018$307.00K–
Q3 FY2018CQ2 2018Jun 30, 2018$443.00K–
Q1 FY2018CQ4 2017Dec 31, 2017$231.00K–

More Autolus Therapeutics figures

See a number that looks wrong?